These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17892924)

  • 21. 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma.
    Celentano L; Sullo P; Klain M; Lupoli G; Cascone E; Salvatore M
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):131-3. PubMed ID: 9002771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
    Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Hanley D; Herskovic T; Markowitz A; Siegel J; Goldenberg DM
    Cancer Res; 1995 Dec; 55(23 Suppl):5946s-5951s. PubMed ID: 7493375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
    Bodei L; Handkiewicz-Junak D; Grana C; Mazzetta C; Rocca P; Bartolomei M; Lopera Sierra M; Cremonesi M; Chinol M; Mäcke HR; Paganelli G
    Cancer Biother Radiopharm; 2004 Feb; 19(1):65-71. PubMed ID: 15068613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis.
    Treglia G; Villani MF; Giordano A; Rufini V
    Endocrine; 2012 Dec; 42(3):535-45. PubMed ID: 22527889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors.
    Shapiro B; Sisson JC; Shulkin BL; Gross MD; Zempel S
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):3-8. PubMed ID: 9002740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
    Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
    Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatostatin and somatostatin analogues in medullary thyroid carcinoma.
    O'Byrne KJ; O'Hare N; Sweeney E; Freyne PJ; Cullen MJ
    Nucl Med Commun; 1996 Sep; 17(9):810-6. PubMed ID: 8895910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC).
    Kurtaran A; Leimer M; Kaserer K; Yang Q; Angelberger P; Niederle B; Virgolini I
    Nucl Med Biol; 1996 May; 23(4):503-7. PubMed ID: 8832707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals.
    Wong KK; Laird AM; Moubayed A; Chondrogiannis S; Marzola MC; Evangelista L; Gross MD; Rubello D
    Nucl Med Commun; 2012 Jul; 33(7):679-88. PubMed ID: 22422100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
    Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
    Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
    Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
    J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Accumulation of radioactivity in the lung after 111In-octreotide scintigraphy].
    Schleicher UM; Cremerius U; Schubert H
    Rofo; 1998 Apr; 168(4):404-6. PubMed ID: 9589108
    [No Abstract]   [Full Text] [Related]  

  • 35. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
    Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
    Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iodine 123 metaiodobenzylguanidine radio-guided navigation surgery for recurrent medullary thyroid carcinoma in a girl with multiple endocrine neoplasia type 2B.
    Shimotake T; Tsuda T; Aoi S; Fumino S; Iwai N
    J Pediatr Surg; 2005 Oct; 40(10):1643-6. PubMed ID: 16226999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
    Stein R; Juweid M; Mattes MJ; Goldenberg DM
    Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
    Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
    J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.
    Szakáll S; Esik O; Bajzik G; Repa I; Dabasi G; Sinkovics I; Agoston P; Trón L
    J Nucl Med; 2002 Jan; 43(1):66-71. PubMed ID: 11801705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Localization of hepatic metastases by radiolabelled anti-carcinoembryonic antigen antibody and meta-iodobenzylguanidine in a patient with medullary thyroid carcinoma.
    Liewendahl K; Välimäki M; Taavitsainen M
    Eur J Nucl Med; 1993 Jun; 20(6):551-4. PubMed ID: 8339736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.